News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
135,829 Results
Type
Article (9332)
Company Profile (63)
Press Release (126434)
Section
Business (42615)
Career Advice (161)
Deals (6615)
Drug Delivery (22)
Drug Development (25427)
Employer Resources (22)
FDA (3424)
Job Trends (4021)
News (76053)
Policy (5431)
Tag
2024 BioCapital Digital (1)
2024 BioForest Digital (1)
2024 BioMidwest Digital (1)
2024 Bio NC Digital (2)
2024 Biotech Bay Standard (2)
2024 Biotech Beach Standard (1)
2024 Genetown Standard (3)
2024 Pharm Country Standard (2)
2026 BioMidwest Elite (1)
2026 Biotech Bay Elite (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Elite (1)
2026 Pharm Country Standard (1)
Academia (377)
Adcomms (10)
Allergies (9)
Alliances (12164)
ALS (10)
Alzheimer's disease (148)
Antibody-drug conjugate (ADC) (83)
Approvals (3456)
Artificial intelligence (76)
Autoimmune disease (3)
Automation (1)
Bankruptcy (58)
Best Places to Work (3555)
BIOSECURE Act (3)
Biosimilars (36)
Biotechnology (53)
Bladder cancer (45)
Brain cancer (21)
Breast cancer (173)
Cancer (1318)
Cardiovascular disease (24)
Career advice (129)
Career pathing (4)
CAR-T (68)
Cell therapy (150)
Cervical cancer (8)
Clinical research (21083)
Collaboration (295)
Compensation (80)
Complete response letters (2)
COVID-19 (394)
CRISPR (10)
C-suite (85)
Cystic fibrosis (1)
Data (624)
Decentralized trials (1)
Depression (5)
Diabetes (25)
Diagnostics (1328)
Digital health (3)
Diversity (1)
Diversity, equity & inclusion (7)
Drug discovery (42)
Drug pricing (26)
Drug shortages (1)
Duchenne muscular dystrophy (4)
Earnings (13920)
Editorial (11)
Employer branding (8)
Employer resources (22)
Events (23855)
Executive appointments (227)
FDA (3689)
Featured Employer (12)
Fibrodysplasia Ossificans Progressiva (1)
Frontotemporal dementia (1)
Funding (150)
Gene editing (17)
Generative AI (8)
Gene therapy (54)
GLP-1 (128)
Government (611)
Guidances (12)
Healthcare (4262)
Huntington's disease (5)
IgA nephropathy (10)
Immunology and inflammation (28)
Indications (10)
Infectious disease (412)
Inflammatory bowel disease (27)
Inflation Reduction Act (2)
Influenza (4)
Intellectual property (18)
Interviews (26)
IPO (3125)
IRA (18)
Job creations (693)
Job search strategy (123)
Kidney cancer (10)
Labor market (2)
Layoffs (160)
Leadership (2)
Legal (798)
Liver cancer (39)
Lung cancer (220)
Lymphoma (66)
Management (5)
Manufacturing (42)
MASH (4)
Medical device (895)
Medtech (895)
Mergers & acquisitions (3587)
Metabolic disorders (64)
Multiple sclerosis (10)
NASH (1)
Neurodegenerative disease (7)
Neuropsychiatric disorders (1)
Neuroscience (217)
NextGen: Class of 2025 (1094)
Non-profit (534)
Northern California (700)
Now hiring (7)
Obesity (37)
Opinion (56)
Ovarian cancer (47)
Pain (5)
Pancreatic cancer (45)
Parkinson's disease (19)
Partnered (1)
Patents (39)
Patient recruitment (25)
Peanut (6)
People (14803)
Pharmaceutical (14)
Pharmacy benefit managers (1)
Phase I (7799)
Phase II (8847)
Phase III (6936)
Pipeline (294)
Podcasts (17)
Policy (28)
Postmarket research (585)
Preclinical (2429)
Press Release (2)
Prostate cancer (63)
Psychedelics (2)
Radiopharmaceuticals (166)
Rare diseases (60)
Real estate (871)
Recruiting (8)
Regulatory (4503)
Reports (8)
Research institute (707)
Resumes & cover letters (30)
RSV (8)
Schizophrenia (13)
Series A (37)
Series B (10)
Service/supplier (1)
Sickle cell disease (19)
Southern California (543)
Special edition (3)
Sponsored (5)
Startups (924)
State (1)
Stomach cancer (10)
Supply chain (9)
The Weekly (17)
United States (5051)
Vaccines (120)
Venture capitalists (14)
Webinars (3)
Weight loss (20)
Women's health (2)
Date
Last 7 days (174)
Last 30 days (700)
Last 365 days (9688)
2025 (1634)
2024 (9970)
2023 (11127)
2022 (14411)
2021 (14275)
2020 (11905)
2019 (9331)
2018 (6925)
2017 (7836)
2016 (6898)
2015 (7622)
2014 (5072)
2013 (3568)
2012 (3843)
2011 (3807)
2010 (3525)
Location
Africa (119)
Alabama (19)
Alaska (1)
Arizona (13)
Arkansas (2)
Asia (11302)
Australia (1534)
California (1425)
Canada (403)
China (212)
Colorado (45)
Connecticut (65)
Delaware (84)
Europe (22446)
Florida (166)
Georgia (6)
Idaho (6)
Illinois (137)
India (5)
Indiana (45)
Japan (60)
Kansas (9)
Kentucky (9)
Maine (3)
Maryland (186)
Massachusetts (1245)
Michigan (16)
Minnesota (61)
Missouri (6)
Montana (5)
Nebraska (3)
Nevada (5)
New Hampshire (8)
New Jersey (382)
New Mexico (2)
New York (345)
North Carolina (172)
Northern California (700)
Ohio (37)
Oklahoma (1)
Oregon (5)
Pennsylvania (225)
Puerto Rico (1)
Rhode Island (3)
South America (152)
South Carolina (2)
Southern California (543)
Tennessee (16)
Texas (232)
Utah (36)
Virginia (12)
Washington D.C. (8)
Washington State (141)
Wisconsin (11)
135,829 Results for "novartis oncology".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Layoffs
Novartis Cuts MorphoSys Sites in Boston, Munich, Affecting 330 Jobs
The closures follow Novartis’s acquisition of MorphoSys earlier this year.
December 19, 2024
·
1 min read
·
Annalee Armstrong
Mergers & acquisitions
Novartis Bets Up to $3.1B to Buy Back Blood Thinner in Anthos Acquisition
Novartis is paying $925 million upfront to acquire Anthos Therapeutics, whose launch the pharma backed in February 2019.
February 11, 2025
·
2 min read
·
Tristan Manalac
Patents
Novartis Scrambles to Squelch Copycats as Generics Gain Ground
Novartis is locked in a legal back-and-forth with MSN Pharma over alleged patent infringement of its heart failure drug Entresto.
January 17, 2025
·
2 min read
·
Tristan Manalac
The Novartis Oncology Young Canadian Investigator Awards (NOYCIA) returns for its 21st year at ASCO 2024
Novartis Canada is pleased to announce the winners of the 2024 Novartis Oncology Young Canadian Investigator Awards, an annual national competition dedicated to advancing oncology through the promotion of research by supporting Canadian oncology researchers.
June 11, 2024
·
4 min read
Earnings
Novartis Eyes More Bolt-On Deals in 2025 as Q4 Earnings Easily Beat Consensus
Novartis was among the most prolific pharma dealmakers in 2024, a trend that it expects to continue with more bolt-on deals this year to set up for sustainable long-term growth.
January 31, 2025
·
2 min read
·
Tristan Manalac
Deals
Mariana Oncology to be Acquired by Novartis to Advance Precision Radiopharmaceuticals to Treat Cancer
Mariana Oncology, a fully integrated biotechnology company pioneering a new era of radiopharmaceutical innovation to treat people with cancer, announced it will be acquired by Novartis for $1 billion upfront and up to $750 million in potential milestone payments.
May 2, 2024
·
3 min read
Legal
Novartis Loses Appeal to Bar Entresto Generic From U.S. Market
Novartis is seeking to prevent the entry of generics for its blockbuster heart failure drug Entresto, its top-selling asset that brought in more than $6 billion in net global sales last year.
December 5, 2024
·
2 min read
·
Tristan Manalac
Mergers & Acquisitions
Novartis CEO Promises More Deals of Up to $5B, With an Eye for Early Science
Novartis has disclosed roughly $19.4 billion in deals in the past five years. CEO Vas Narasimhan says there’s more to come.
November 21, 2024
·
2 min read
·
Annalee Armstrong
Radiopharma
Novartis Drops Up to $745M to Move Deeper Into Competitive Radiopharma Space
The deal has secured Novartis the chance to work with Ratio Therapeutics on a novel drug candidate that could fortify the Big Pharma against competition from would-be radiopharmaceutical rivals such as BMS and Lilly.
November 18, 2024
·
2 min read
·
Nick Paul Taylor
Earnings
Novartis Gets Q3 Beat on Strong Cosentyx Sales, But Pluvicto Disappoints
Novartis exceeded analyst expectations in the third quarter, driven primarily by the strong U.S. sales of Cosentyx, as well as the robust performances of Kesimpta and Kisqali.
October 29, 2024
·
2 min read
·
Tristan Manalac
1 of 13,583
Next
